AMN 082 dihydrochloride
The first selective mGlu7 agonist. Potently inhibits cAMP accumulation and stimulates GTPγS binding in recombinant cells and on membranes expressing mGlu7 (EC50 = 64 - 290 nM). Selective over other mGluR subtypes and selected ionotropic glutamate receptors up to 10 μM. Acts via a novel allosteric site and is orally active and brain penetrant. Reduces haloperidol-induced catalepsy in rats.
View important information regarding the usage of AMN 082 dihydrochloride.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||0.93||2mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 465.45. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.15 mL||10.74 mL||21.48 mL|
|5 mM||0.43 mL||2.15 mL||4.3 mL|
|10 mM||0.21 mL||1.07 mL||2.15 mL|
|50 mM||0.04 mL||0.21 mL||0.43 mL|
References are publications that support the products' biological activity.
Greco et al (2010) Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease. J.Pharmacol.Exp.Ther. 332 1064 PMID: 19940105
Flor et al (2005) AMN082, the first selective mGluR7 agonist: activation of receptor signaling via an allosteric site in the transmembrane domain modulates stress parameters in vivo. Neuropharmacology 49 244 PMID:
Mitsukawa et al (2005) A selective metabotropic glutamate receptor 7 agonist: Activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc.Natl.Acad.Sci.USA 102 18712 PMID:
If you know of a relevant reference for AMN 082 dihydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: AMN 082 dihydrochloride, supplier, selective, mGlu7, mGluR7, agonists, mGlur, Group, III, Receptors, Glutamate, Metabotropic, AMN082, dihydrochloride, Glutamate, (Metabotropic), Group, III, Receptors, Glutamate, (Metabotropic), Group, III, Receptors, Tocris Bioscience
1 Citation for AMN 082 dihydrochloride
Citations are publications that use Tocris products. Selected citations for AMN 082 dihydrochloride include:
Broadstock et al (2012) Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata. Br J Pharmacol 165 1034 PMID: 21627638
Do you know of a great paper that uses AMN 082 dihydrochloride from Tocris? If so please let us know.
Reviews for AMN 082 dihydrochloride
There are currently no reviews for this product. Be the first to review AMN 082 dihydrochloride and earn rewards!
Have you used AMN 082 dihydrochloride?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.